Linzess denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for linzess are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Linzess as Experimental

An experimental or investigational denial for Linzess (linaclotide) is unusual given the drug's FDA approval status, but it can occur when Aetna's coverage policy applies an experimental classification to a specific indication, population, or dosing regimen that differs from the approved labeling — for example, use in an age group, diagnosis subtype, or off-label application not covered by Aetna's clinical criteria. It can also result from a coverage policy that has not been updated to reflect current FDA-approved indications. Understanding precisely which indication or use Aetna is calling experimental is essential before crafting your appeal.

## Why This Denial Is Appealable

Linzess is FDA-approved for specific indications in adults, and its approval is documented in publicly available FDA records. If Aetna's experimental denial applies to an FDA-approved indication used consistent with the approved labeling, the denial is factually incorrect and should be challenged on that basis directly. If the denial relates to an off-label use, the appeal strategy should focus on the strength of published evidence and applicable guideline society support for that use, as presented by your prescriber. Experimental denials are explicitly eligible for external review under ACA §2719 and are frequently reversed.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice. Request the specific coverage policy and clinical criteria Aetna applied so you can respond to each element.
• External review: Experimental/investigational denials are expressly eligible for independent external review under ACA §2719. The standard window is approximately 4 months from the final internal denial; confirm the exact deadline on your Explanation of Benefits.
• Expedited option: If your condition is urgent, expedited external review decisions are typically required within 72 hours of the IRO receiving a complete file.
• State protections: Some states have additional external review protections for experimental denials that may expand your rights beyond federal minimums.

## Documentation to Gather

1. FDA approval record — print the Linzess approval page from fda.gov, including the approved indications statement. This is your primary exhibit if the denial is applied to an FDA-approved use. 2. FDA-approved prescribing information — the full label confirms approved indications, populations, and conditions of use. Confirm your use matches an approved indication. 3. Diagnosis confirmation — clinical notes and objective findings establishing your IBS-C or CIC diagnosis consistent with the FDA-approved indication. 4. Prescriber medical-necessity letter — must identify which indication Aetna called experimental, cite the FDA approval status or published evidence for that use, and address each element of Aetna's coverage criteria directly. 5. Prior-treatment history — documentation that other approaches have been inadequate, supporting the clinical necessity of Linzess specifically. 6. Guideline references — your prescriber should reference applicable gastroenterology society guidelines (e.g., ACG, AGA) by organization name to support the evidence base for treatment.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy for Linzess and identify precisely which element triggers the experimental classification. Map each criterion to your evidence: FDA approval documentation for the relevant indication, chart-based diagnosis confirmation, prior treatment failure, and guideline support. If Aetna's policy cites a specific evidence standard, ask your prescriber to address each component of that standard in their letter. A point-by-point response reduces the reviewer's ability to sustain the denial on a general evidentiary basis.